MicroRNAs: A Novel Therapeutic Target for Schizophrenia

Author(s): Javier A. Bravo, Timothy G. Dinan

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 2 , 2011


Become EABM
Become Reviewer
Call for Editor

Abstract:

Schizophrenia is one of the most disabling psychiatric conditions. Current treatments target monoamine receptors but this approach does not address the full complexity of the disorder. Here we explore the possibility of developing new anti-psychotics by targeting microRNAs (miRNAs), single stranded RNA molecules, 21 – 23 nucleotides in length that are not translated into proteins and regulate gene expression. The present review reveals that research involving schizophrenia and miRNA is very recent (the earliest report from 2007) and miRNAs add a significant layer of complexity to the pathophysiology of the disorder. However, miRNAs offer an exciting potential not only to understand the underlying mechanisms of schizophrenia, but also for the future development of antipsychotics, as the human miRNA system provides a rich and diverse opportunity for pharmacological targeting. However, technology is still developing in order to produce effective strategies to modulate specific and localized changes in miRNA, particularly in relation to the central nervous system and schizophrenia.

Keywords: Schizophrenia, miRNA, antipsychotics, non-coding nucleic acids

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2011
Page: [176 - 188]
Pages: 13
DOI: 10.2174/138161211795049543
Price: $65

Article Metrics

PDF: 7